← Back to Search

mGlide Mobile Health Intervention for High Blood Pressure

N/A

Recruiting

Led By Kamakshi Lakshminarayan, MD, PhD

Research Sponsored by University of Minnesota

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Diagnosis of uncontrolled HTN at the time of study enrollment (need not have had a stroke)

Stroke survivors (ischemic stroke or intra-parenchymal hemorrhage) or patients at high risk of stroke or cardiovascular disease (CVD) events (>7.5% over 10 years)

Must not have

Any severe co-morbid illness including end stage kidney disease (ESRD), end stage liver disease (ESLD) or life expectancy less than 1 year or if primary care provider feels that medical complexity of the patient precludes clinical trial participation

Unable to complete study tasks

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing whether a mobile health intervention can improve blood pressure control in stroke survivors and high-risk patients without stroke.

Who is the study for?

This trial is for adults with uncontrolled high blood pressure, especially those at high risk of stroke or heart disease. Participants must speak English, Spanish, or Hmong and be able to use a smartphone compatible with the BP monitoring app. Stroke survivors are also eligible. People with severe illnesses like end-stage kidney/liver disease or serious psychiatric conditions cannot join.

What is being tested?

The mGlide RCT tests if using mobile health technology can better manage high blood pressure in patients at risk of cardiovascular diseases. It involves daily self-monitoring of BP via a wireless monitor and smartphone, alerting healthcare teams when readings deviate from expected levels.

What are the potential side effects?

Since mGlide is a mobile health intervention focused on monitoring and managing blood pressure rather than a medication, it does not have direct side effects like drugs do. However, there may be indirect effects related to stress or anxiety from constant health monitoring.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have high blood pressure that isn't well-controlled.

Select...

I have survived a stroke or am at high risk for stroke or heart disease.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I do not have severe kidney, liver disease, or any condition that limits my life to under a year.

Select...

I am unable to perform tasks required by the study.

Select...

I speak English, Spanish, or Hmong.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

HTN control into guideline specified range

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: mGlide InterventionExperimental Treatment1 Intervention

Participants will be educated on HTN and taught to self-monitor their BP. The transmitted BP will be used for adjustment of anti-HTN medications as it occurs in clinical practice.

Group II: Clinical Care ComparisonActive Control1 Intervention

Patients will be educated similar to intervention and taught self-monitoring of BP. Then they will be asked to follow up with primary care as usual.

0 / 5Eligibility criteria met